BridgeBio Inc


421 Kipling StPalo AltoCalifornia94301United States View Map


$7 Million




(650) 521-0894


BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat rare diseases at their source. Founded in 2015 by a team of industry veterans who previously brought more than a dozen products to market, BridgeBio has built a robust portfolio of ten transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology. The drugs are in various phases of development, from pre-clinical to late-stage. With a commitment to scientific excellence and rapid execution, BridgeBio aims to translate today's discoveries into tomorrow's medicines.

Read More

Recently Updated profiles at this company

Chief Executive Officer and Founder

Vice President of Asset Acquisition, Strategy and Operations

Browse ZoomInfo’s Directories